Clinical Trial Update: Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

View source ↗

Summary

Analysis of EBMT registry data evaluates off-label use of plerixafor in hematopoietic cell transplantation, summarizing indications and observed outcomes and sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Disorders
• Solid Tumors

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Acute Leukemia, Chronic Leukemia | Status: COMPLETED